Astellas Pharma and Pfizer have received the Food and Drug Administration’s permission for Xtandi (enzalutamide). Xtandi is the first and only androgen receptor signaling inhibitor approved by the FDA ...

The Food and Drug Administration approved Xtandi for non-metastatic castration-sensitive prostate cancer at high risk for biochemical recurrence. The Food and Drug Administration (FDA) approved Xtandi ...

When compared with Zytiga, Xtandi appeared to have a lower incidence of infection among men with prostate cancer, especially those under 70 years. The utilization of Xtandi (enzalutamide), compared ...

XTANDI: the first and only androgen receptor inhibitor-based regimen to demonstrate overall survival benefit in non-metastatic hormone-sensitive prostate cancer (nmHSPC) with high-risk biochemical ...

ESSA Pharma (EPIX) (EPI:CA) is a clinical-stage oncology company focused on developing treatments against prostate cancer and is based in Vancouver, Canada. The company has been in the investor ...

XTANDI becomes the first and only androgen receptor signaling inhibitor approved for use with or without a GnRH analog therapy* in nonmetastatic castration-sensitive prostate cancer Of men who have ...

In the fall of 2020, Robert Sachs was prescribed a medication to treat prostate cancer that had metastasized into some of his bones. He welcomed the treatment, but was surprised by the $740 monthly ...

In the final days of the Biden administration, the U.S. Department of Health and Human Services’ Centers for Medicare and Medicaid Services (CMS) laid out the latest 15 drugs that are subject to ...

For the third time in less than a year, a group of lawmakers is urging the Biden administration to use a controversial provision of federal law to widen access to a pricey cancer medicine, an issue ...

The Department of Health and Human Services, through the Centers for Medicare & Medicaid Services, announced the selection of 15 additional drugs covered under Medicare Part D for price negotiations.